feed,title,long_url,short_url
Benzinga,"Kodiak Sciences Announces 1-Year Durability, Efficacy and Safety Data from Ongoing Phase 1b Study of KSI-301 in Patients with Wet Age-Related Macular Degeneration, Diabetic Macular Edema and Retinal Vein Occlusion at the Angiogenesis, Exudation and Degeneration 2021 Annual Meeting",https://www.benzinga.com/pressreleases/21/02/n19654516/kodiak-sciences-announces-1-year-durability-efficacy-and-safety-data-from-ongoing-phase-1b-study-o,https://j.mp/3b64jV9
